Comparison of the efficacy of carpisetin/tripodin and fulvestrant, which one is better?

Capivasertib is an oral small molecule kinase inhibitor that mainly acts on the AKT signaling pathway and blocks the growth and proliferation signals of tumor cells. Fulvestrant is a selective estrogen receptor degrader (SERD) that blocks the growth-promoting effect of estrogen signals on breast cancer cells by degrading hormone receptors. There are significant differences in mechanisms between the two, which also determines the focus of their clinical application.

Fulvestrant has long been widely used as a single agent in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It is especially suitable for patients who are sensitive to endocrine therapy and do not have key genetic changes. However, for those patients with gene mutations such as PIK3CA, AKT1 or PTEN, tumor cells often acquire resistance to endocrine therapy by activating the downstream AKT pathway. In this case, the efficacy of fulvestrant alone is limited.

Carpiseti breaks the resistance mechanism by directly inhibiting theAKT signaling pathway, especially when used in combination with fulvestrant, it shows a significant synergistic effect. Clinical studies have shown that for patients who still experience disease progression after previous endocrine therapy, capicipositi combined with fulvestrant can delay disease progression, increase the objective response rate, and improve the survival outcomes of some patients. Compared with fulvestrant alone, the combination regimen can precisely target the molecular characteristics of tumors, thereby providing more effective treatment options in drug-resistant settings.

In terms of safety, the treatment of capicipositi combined with fulvestrant also showed a controllable spectrum of adverse reactions. Common adverse events include mild to moderate diarrhea, rash, fatigue, and blood glucose fluctuations, which are often effectively managed with dose adjustment and supportive care. In contrast, single-agent fulvestrant has milder adverse effects but may not be able to significantly control tumor progression in patients with high-risk genetic alterations.

In addition, the oral administration method of capisetib provides patients with high convenience and can be used for a long time in an outpatient or home environment, while fulvestrant needs to be administered by injection, and the treatment process is relatively dependent on medical institutions, affecting the patient's quality of life. For patients with advanced or metastatic breast cancer, the convenient administration method and precise intervention in the resistance mechanism make capicistat combined with fulvestrant show wider application potential in clinical practice.

In general, forFor HR-positive, HER2-negative breast cancer patients with PIK3CA, AKT1 or PTEN gene alterations, fulvestrant alone may not be able to fully overcome the drug resistance problem. However, the combination therapy of capicipositi and fulvestrant significantly improves the efficacy and disease control rate by targeting the AKT signaling pathway and maintaining estrogen receptor inhibition. Therefore, from the perspective of precise treatment and clinical results, the efficacy of capicipositin combined with fulvestrant is better than that of fulvestrant alone in breast cancer patients with specific genetic backgrounds, providing a more effective clinical treatment option.

Reference materials:https://www.drugs.com/mtm/capivasertib.html